The primary end point of PROGRESS was incidence of all stroke (whether fatal or non fatal).
Secondary end points included fatal or disabling strokes, total cardiovascular events (non fatal stroke, non fatal myocardial infarction, or cardiovascular death), total deaths, hospital admissions, and dementia and cognitive decline.
References
Neal B, MacMahon S.
PROGRESS (perindopril protection against recurrent stroke
study): rationale and design. PROGRESS Management Committee J
Hypertens. 1995 Dec;13(12 Pt 2):1869-73. Stroke Trials Directory: PROGRESS
